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Summary TRKA expression was evaluated on 122 untreated neuroblastomas by immunohistochemistry using an antibody with
predetermined specificity. This procedure is simple and reliable for protein detection at cellular level in a routine clinical setting. Fourteen
tumours were classified as benign ganglioneuroma with a restricted expression of TRKA on ganglion cells; these patients were excluded from
the following analysis. A total of 108 tumours were classified as neuroblastoma organglioneuroblastoma; 74 expressed TRKA protein, which
strongly correlated with low stage, absence of N-MYC amplification, age (<1 year), CD44 expression and favourable clinical outcome. In a
univariate analysis including tumour stage, age, histology, N-MYCamplification, CD44 and TRKA expression, all parameters had significant
prognostic value. The absence of TRKA expression on CD44-positive or N-MYC non-amplified tumours permits the characterization of a
subgroup of patients with intermediate prognosis. However, in a multivariate analysis taking into consideration the prognostic factors
mentioned above, CD44 and tumour stage were the only independent prognostic factors for the prediction of patients' event-free survival.
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Neuroblastoma, the most frequent solid tumour in children below
5 years ofage, is characterized by its very peculiar clinical behav-
iour. In the vast majority ofinfants with stage IVS neuroblastoma,
the tumours regress spontaneously and, for many children with
stage I or II disease, minimal treatment is sufficient. However, in
most cases neuroblastoma is metastatic at diagnosis; in children
over 1 year of age, these stage IV tumours grow relentlessly and
lead to fatal evolution even when being treated with the most
aggressive radiochemotherapy protocols (Philip et al, 1987;
Zucker et al, 1991). Although the clinical stage ofthe disease and
the age ofthe children atdiagnosis allow aprognosis to be made in
most cases (Evans et al, 1971), progress in the management of
neuroblastoma still requires a more precise evaluation based on
the characterization ofbiological abnormalities. Several cellularor
molecular abnormalities have been found to be associated with
aggressive forms of the disease and unfavourable outcome
(Shimada et al, 1984; Brodeur et al, 1992; Nakagawara et al, 1993;
Favrot et al, 1993), but most of them are stage dependent and
likely not to be truly independent. Their prognostic significance
must now be compared in multifactorial analyses. Furthermore,
the technique used to define these biological parameters must be
adapted to a routine clinical setting, i.e. the techniques must allow a
reliable, simple and reproducible evaluation on clinical samples with
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by normal cells. Among these biological parameters, the amplifica-
tion ofN-MYCproto-oncogene is considered as a reference marker
present in aggressive tumours and assessed by most ofthe groups.
Morerecently, theexpression oftwo membrane molecules has been
shown to have prognostic significance: CD44 adhesion molecule
(Favrot et al, 1993; Gross etal, 1994; Combaret et al, 1996) and the
NGF receptor (TRKA glycoprotein) (Nakagawara etal, 1993).
The cell surface glycoprotein CD44 is a polymorphic molecule
resulting from altemative splicing and cell lineage-specific glyco-
sylation. The most prevalent isoform ofCD44 is an 80- to 90-kDa
molecule named CD44H (H standing for haematopoietic). CD44
acts as the principal receptorforhyaluronate and is involved in the
homing process and cell-cell or cell-extracellular matrix interac-
tions. As expected fromexperimental models, an analysis ofCD44
expression on human malignant tissues, mostly breast or colon
cancers and lymphomas, has shown that they overproduced large
altematively spliced molecular variants of CD44, with a striking
difference between metastatic and non-metastatic malignant spec-
imens (see Favrot et al, 1993; Gross et al, 1994; Combaret et al,
1996 for reference). In contrast with these previously described
models, we have shown that the lack of CD44 on neuroblastoma,
as determined by immunohistochemistry, is a highly significant
indicator ofpoor prognosis (Favrot et al, 1993; Gross et al, 1994;
Combaret et al, 1996).
The analysis of TRKA glycoprotein expression in neuroblas-
toma has been based on the argument that the differentiation (or
regression) may involve an interaction between the neurotrophin
nerve growth factor (NGF) and its receptor. NGF acts through a
specific receptor defined as glycoprotein gpl4O TRKA, the
product of the TRKA gene. This transmembrane tyrosine kinase
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may function either alone or in complex with another transmem-
brane glycoprotein called gp75 LNGFR. The biological responsive-
ness to NGF depends on interactions with TRKA (see Nakagawara
etal, 1993; Kogner etal, 1993; Susuki etal, 1993 forreference). The
association between high levels of TRKA expression and
favourable outcome has been observed in different studies in which
TRKA expression was studied using Northern blot or reverse tran-
scriptase polymerase chain reaction (RT-PCR) (Nakagawara et al,
1993; Kogner et al, 1993; Susuki et al, 1993; Borrello et al, 1993).
Although the second method limits the amount of tissue necessary
for the analysis, both methods have several limitations. The major
one is that they provide a global evaluation of the TRKA mRNA
present in the sample without a precise estimation ofits expression
on single malignant cells, involving errors linked to contamination
ofthe samples by normal cells.
In order to overcome these limitations, we evaluated TRKA
expression by immunohistochemistry, as previously done for CD44
analysis, on 108 untreated neuroblastoma specimens and 14
ganglioneuromas. We then analysed the prognostic value of TRKA
expression in amultivariateanalysis includingthe stageofthedisease,
the age ofthe children, the histology ofthe tumour, the expression of
CD44 and the presence or absence ofN-MYCamplification.
PATIENTS, MATERIAL AND METHODS
Patients and therapy
Specimens were obtained from 122 untreated patients in France or
Switzerland from January 1987 to September 1995. Thirty-seven
patients were identified and treated in Lausanne University
Hospital and co-operative institutions in Switzerland; 85 patients
were identified and treated in the Centre for Cancer Treatment in
Lyon or co-operative institutions in France. Neuroblastoma diag-
nosis and staging were performed according to Evans's criteria
(Evans et al, 1971). Staging was as follows: stage I, tumour
confined to the organ or structure of origin; stage II, tumour
extending in continuity beyond the organ or structure oforigin but
not crossing the midline, possibly with homolateral involvement
ofregional lymph nodes; stage III, tumour extending in continuity
beyond the midline, possibly with bilateral involvement of
regional lymph nodes; stage IV, large primary tumour with remote
disease involving multiple sites, including bone, bone marrow,
organs, soft tissues or groups of distant lymph nodes; and stage
IVS, in infants less than 1 year of age with small primary tumour
similar to tumour in stage I or II, but with remote tumour in liver,
skin or bone marrow (not bone).
During the same period, a total of 224 patients with neuroblas-
toma were seen at one or the other institution. The selection of
patients for the study was based solely on the availability ofsuffi-
cient amounts of tumour tissue for DNA and immunohistological
analyses. The stage distribution in analysed patients shows a
disproportionate occurrence of low stage I and II compared with
stage III and IV. This is because high-grade neuroblastomas only
have surgical tumour resection after induction chemotherapy; the
material obtained by ultrasound-guided puncture at diagnosis
might thus not be sufficient for DNA and immunohistological
analyses and storage. Although the event-free survival of all
patients, as expected from stage distribution, was slightly different
between included and excluded patients, selection of the patients
should not have biased the results; indeed, there is no significant
difference between the event-free survival of patients included in
the study and patients excluded from it when the analysis is based
on the stage of the disease. Event-free survival rates of the two
cohorts of children (Switzerland and France) were not signifi-
cantly different (P=0.64).
Children were treated with the same well-standardized proto-
cols in each institution, as previously described (Philip et al, 1987;
Zucker et al, 1991). Patients with stage I disease and most patients
with stage II or IVS disease were treated with surgery alone; a few
patients with stage II or IVS disease received chemotherapy or
local irradiation. Patients with stage III and IV disease were
treated with well-standardized induction chemotherapy followed
by surgery and, occasionally, by additional local radiotherapy.
Then stage IV patients older than 1 year of age received consoli-
dation with high-dose chemotherapy, with or without total-body
irradiation, followed by autologous bone marrow transplantation;
this treatment was also used for stage III patients who did not
respond to first-line therapy and for those who relapsed. Infants
less than 1 yearofage with stage IV disease received only conven-
tional induction chemotherapy followed by surgery; only one of
these infants had N-MYC-amplified tumour and received high-
dose chemotherapy without total-body irradiation and autologous
bone marrow transplantation. The mean follow-up time for
survivors was 35 months (range 1-124 months).
Tumour specimens
Specimens were stored and analysed in two different laboratories
using the same techniques described later. Results were repro-
ducible from one laboratory to the other. Tumoral specimens were
obtained at diagnosis by surgical biopsy or excision ofthe primary
tumour in stage I, II and IVS disease, or by ultrasound-guided
puncture of the primary tumour in stage III and IV disease. In a
few stage IV patients, malignant cells were obtained from highly
contaminated bone marrow aspirates (> 50% malignant cells
within the mononuclear cell population). Bone marrow aspirates
and ultrasound-guided punctures were harvested on heparinized
medium and purified by density gradient separation (Ficoll;
Eurobio, Les Ulis, France). Half was kept for molecular analysis,
whereas cytological and immunological analyses were performed
on centrifuged smears, as previously described (Favrot et al, 1991;
Combaret et al, 1996). Primary tumour samples were taken surgi-
cally and divided into three parts, judged to be representative of
the same lesion: one part was kept for histological analysis (Bouin
fixation), one was kept for molecular analysis and the third part was
frozen in isopentane for immunological analysis (Favrot et al, 1991).
Southern blot analysis
N-MYC was analysed by the Southern blot technique, as previously
described (Combaret et al, 1989). After extraction, DNA was
digested with restriction endonuclease EcoRI. A 10-jg quantity of
DNA was loaded per lane, electrophoresed through 1% agarose
and transferred to nylon filters (Pall Europe, Portsmouth, UK).
Hybridization was performed with the NMYC probe pNb-l (kindly
provided by J Minna, NCI, Bethesda, MD, USA) 32P-labelled by
Amersham (Little Chalfont, UK) Multiprime DNA Labelling
System to a specific activity ofapproximately 109 c.p.m. jg-1.
In N-MYC analysis, restriction enzyme-digested tumour DNAs
were compared in the same agarose gels (two-copy intensity) with
lymphocyte DNA and with the known N-MYC-amplified DNA of
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a neuroblastoma cell line (SKNBE: 100-copy intensity). The
number of amplified gene copies was measured by serial dilution
ofDNA to obtain a hybridization signal oftwo-copy intensity (e.g.
a 100-fold amplification is indicated when a 1:100 dilution
achieves two-copy intensity). The presence of more than two
copies ofN-MYC in all samples was considered as amplification.
Detection of TRKA and CD44 expresion by
immunostaining
The immunohistochemical detection of TRKA was performed
using a rabbit polyclonal IgG (TRK 763) directed against amino
acids 763-777 mapping adjacent to the carboxy terminus
TRK.gpl40 (Santa Cruz Biotechnology, Santa Cruz, USA), and
alkaline phosphatase immunostaining. Briefly, air-dried slides
(cryostat sections or cytocentrifuged smears) were fixed for 5 min
with acetone at 4°C, incubated for 30 min with rabbit polyclonal
antibody TRK 763 used at 1:100 dilution, then for 30 min with
biotinylated swine anti-rabbit immunoglobulins (Dakopatts) and
30 min with a drop of AB complex/AP (Dakopatts). Washes were
done with Tris buffer. The final step consisted ofa 15-min incuba-
tion with Naphthol-As-Mx phosphate, dimethylformamide,
levamisole and fast red (Sigma, St Louis, MO, USA). Antiserum
763 preincubated with an excess of the immunizing peptide was
used as a negative control in all experiments.
Cell surface CD44 expression was detected byJ173 (Immunotech,
Luminy, France) or F1044-2 (British Biotechnology, Oxon, UK)
monoclonal antibodies directed against an epitope in the CD44
constant region, as previously described (Favrot et al, 1993; Gross et
al, 1994; Combaret et al, 1996).
The samples were classified as positive for TRKA or CD44
expression when over 10% of tumour cells showed a moderate or
strong reactivity with the antibodies. However, in almost all posi-
tive samples, staining was strong and homogeneous in the whole
malignant population for CD44 as well as TRKA.
Lymphocytes and monocytes were quantified by immuno-
staining with anti-CD45 panleucocyte MAb, and neuroblastoma
cells with anti-CD56; anti-CD45, anti-CD56 and all enzyme-
conjugated immunoglobins were purchased from Dakopatts
(Copenhagen, Denmark). Cytological or histological analyses
were performed in parallel on each specimen by standard tech-
niques. Tumours were classified histologically as typical neurob-
lastoma, ganglioneuroblastoma or ganglioneuroma, as previously
described (Favrot et al, 1991).
In the interpretation of results on bone marrow cytocentrifuged
smears or ultrasound-guided puncture, tumour cells were distin-
guished from haematopoietic cells according to cytological
features, and the analysis of malignant cells was focused on those
which formed typical clumps on the smear.
Statistical analysis
Statistical comparisons between subgroups were performed using
the chi-square test. Event-free survival was calculated according to
the method of Kaplan and Meier. End points were the date of the
first event, i.e. progression ordeath, and the date ofthe last follow-
up evaluation when no event occurred (Kaplan and Meier, 1958).
Curves were compared using the log-rank test.
Multivariate analysis was performed using the Cox proportional
hazards model (Mantel and Haenzel, 1959). All statistical analyses
were performed according to the procedure ofthe BMDP package
(BMDP Statistical Software, Los Angeles, CA, USA).
RESULTS
TRK glycoprotein expression and its correlation with
disease stage, age of the children, CD44 expression
and N-MYCamplification
The expression of TRK glycoprotein was studied by immuno-
chemistry on 122 tumour samples. Fourteen samples were classi-
fied as ganglioneuromas. TRKA expression was observed on the
only two samples that contained ganglion cells and was restricted
to this subpopulation, whereas Schwann cells were negative.
Ganglioneuromas, which are known to be benign tumours, were
excluded from the rest ofthe analysis.
The other 108 samples were classified as neuroblastomas or
ganglioneuroblastomas. Apositive immunostaining was observed on
60 ofthe92neuroblastomas and 14ofthe 16ganglioneuroblastomas.
A strong expression ofTRKA was detected on the 12 stage IVS
neuroblastomas and in most low-stage neuroblastomas (stage I, II
and III) (44/50), whereas it was present on only 18 of46 stage IV
specimens. Therefore, TRK proto-oncogene expression was
strongly related to the stage of the disease (P < 10-5, X2=29.75).
Similarly, TRK expression was strongly correlated with the youth
of the patients, since TRK was found in all but two tumours from
infants, and in only 29 of 61 tumours from patients older than 1
year (P < 10-5, X2 = 26.40).
The expression of TRKA also correlated with the two other
biological markers, i.e. N-MYC and CD44. Among the 108
analysed tumour samples, N-MYC amplification was defined for
105 specimens. Within the 25 tumours with N-MYCamplification,
only eight expressed TRKA, whereas 17 did not. In contrast,
within the 80 non-amplified samples, 63 expressed the TRKA
proto-oncogene (P = 4 x 10-5, X2 = 16.94). Seventy of 85 CD44-
positive samples expressed TRKA, whereas only fourof23 CD44-
negative specimens were TRKA positive (P < 10-5, X2 = 32.47).
Event-free survival according to NMYC amplification,
TRK and CD44 expression
The expression of TRKA strongly correlated with survival
(P = 10, LR = 28.6). Event-free survival at 3 years reached 81%
in the group of patients with TRKA-positive tumours, whereas it
was only 27% in TRKA-negative patients. When event-free
survival was analysed according to the N-MYC status of the
tumour, the survival rate at 3 years was 78% in the group of
patients with non-amplified tumours vs 17% in patients with
NMYC amplification. When event-free survival was analysed
according to CD44 expression, the survival rate at 3 years was
78% in the group ofpatients with CD44-positive tumours vs only
13% in patients with tumours that did not express CD44.
Figure IA shows survival according to pattems of both TRK
expression and N-MYC amplification. The combination ofthe two
markers allowed us to distinguish between patients with different
prognosis: patients with TRK-positive and non-N-MYC-amplified
tumours with 88% event-free survival at 3 years, patients with
NMYC amplification and absence ofTRKA expression with 10%
event-free survival and an intermediary group of 25 patients with
only one of the two abnormalities, i.e. NMYC amplification or
TRK negativity (40% event-free survival in 17 patients with
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Table 1 Univariate and multivariate analysis of survival according to clinical
and biological variables in patients with neuroblastoma
Univariate analysis Multivariate analysis
LR P LR P
CD44 expression 39.9 < 10-6 7.98 0.005
N-MYCamplification 32.3 < 10-6 1.11 0.293
TRKA expression 28.6 10-6 2.28 0.131
Age < 12 months 11.6 <10-3 0.49 0.484
Stage 33.04 <10-0 9.99 0.002
Tumour histology 5.3 <0.005 2.39 0.122
The univariate analysis was performed on 108 patients, except for the
evaluation of input of NMYC amplification that was known in only 105







Figure 1 Event-free survival in 108 patients. Combined analysis according to
TRKA expression and NMYC amplification (A). In patients without N-MYC
amplification, event-free survival in patients with or without TRKA expression
was significantly different (LR = 13.7, P < 10), whereas no difference was
observed in the group of patients with NMYC amplification. Combined
analysis according to TRKA expression and CD44 expression (B). In patients
with CD44-positive tumours, event-free survival in patients with or without
TRKA expression was significantly different (LR = 10.8, P < 10 3), whereas no
difference was observed in the group of patients with CD44-negative tumours,
but the number of patients is too small to conclude that TRKA expression is
not of prognostic value. NE, not evaluable; Cl, confidence interval
TRKA-negative andN-MYCnon-amplified tumours, and 32% event-
free survival in the other eight patients with N-MYC-amplified
tumour and TRKA expression).
Figure lB shows survival according to the pattern ofTRKA and
CD44 expression. Within the group of patients with CD44-posi-
tive tumours, the expression ofTRKA permitted us to distinguish
between two groups with significantly different survival, i.e.
patients with TRKA-positive tumours reached 86% event-free
survival at 3 years, although those with TRKA-negative tumours
only reached 38%. Survival at 3 years was less than 15% in
patients with CD44-negative tumours, independently of the
expression of TRKA, but the number of patients is too small to
conclude that TRKA expression is not ofprognostic value.
Univariate and multivariate analyses of clinical and
laboratory variables according to survival
We analysed the effect on survival of the expression of TRKA
compared with other clinical and biological prognostic factors:
patient's age, tumour stage, tumour histology, CD44 expression and
N-MYCamplification (Table 1). On thebasis of aunivariate analysis,
all factors had significant value, but CD44 expression, disease stage,
absence of N-MYC amplification and TRKA expression were the
most powerful predictors of a favourable outcome. In a stage-
related analysis of event-free survival, the absence of N-MYC
amplification, CD44 and TRKA expression were still predictors of
favourable outcome in the group ofpatients with stage I-LI, III and
IVS disease (P<10-3; P=106; P<104 respectively); in stage IV
patients, N-MYC and CD44 remained significant (P=0.02;
P<0.02), but TRKA had no prognostic value (P=0.21). In a multi-
variate analysis taking into consideration the prognostic factors
previously mentioned, CD44 expression and tumour stage were
the only independent prognostic factors for the prediction of
patients' event-free survival.
DISCUSSION AND CONCLUSION
Previous studies have reported that a high level of expression of
the TRKA mRNA in neuroblastoma is strongly predictive of a
favourable outcome (Nakagawara et al, 1993; Kogner et al, 1993;
Susuki et al, 1993; Borrello et al, 1993). Up to now, the analysis of
TRKA by immunohistological methods suffered from a weak defi-
nition of reagent specificity and the absence of evaluation of its
prognostic value. The current study was designed to determine
whether the immunohistochemical expression of the TRKA gene
had a similar clinical relevance and compare its value with that of
already defined parameters, such as N-MYC amplification and
CD44 expression. Thus, the polyclonal antibody that was used is
specific for TRKA and does not show any cross-reactivity for
TRKB or TRKC. During the preparation of this manuscript,
Tanaka et al (1995) reported the immunohistological expression of
TRKA on 105 neuroblastomas using the same reagent and came to
the same conclusion. Unlike Northern blot, the analysis ofTRKA
by immunohistochemistry is a simple and reliable technique for
use in routine clinical study; furthermore, it allows the study of
samples, such as bone marrow aspirates or ultrasound-guided
punctures ofthe primary tumour that contain only small quantities
of tumour cells, or partially differentiated and well-differentiated
tumours because TRKA expression is determined at the cell level
on individual cells. For instance, the selective expression of
TRKA on ganglion cells in ganglioneuromas and the negativity of
Schwann cells were also observed by Donovan et al (1993) with
an immunohistochemical method and might explain that these
fully differentiated tumours express TRKA variably when studied
at RNA level. As previously described for high levels of TRKA
mRNA, TRKA protein expression is associated with young age at
diagnosis, low clinical stage, absence ofN-MYC amplification and
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favourable outcome of the patients. In addition, the expression of
CD44 and that ofTRKA are correlated and the combined analyses
of TRKA expression and N-MYC amplification or CD44 expres-
sion permit the characterization of subgroups of patients with
different prognoses.
The International Neuroblastoma Staging System and Response
Criteria Committee recommend thestudy ofbiological features atthe
time ofdiagnosis in the prediction ofprognosis and for the choice of
the more appropriate therapeutic strategies. Different cellular and
molecular markers have been determined, but the definition of the
mostuseful markers tobeused in aclinical setting suffers from alack
of comparison in multivariate analysis. In our study, four biological
features of the tumour (histology, N-MYC copy number, CD44
expression and TRKA expression) could be analysed concomitantly.
In a univariate analysis, these four parameters had significant value
but, in a multivariate analysis, CD44 expression and disease stage
were the only independent prognostic factors.
In conclusion, the immunohistological detection of TRKA is a
strong prognostic factor in neuroblastoma when combined with
N-MYC or CD44 assessment. In particular, the absence ofTRKA
expression on CD44-positive or N-MYC non-amplified tumours
permits the characterization of a group of patients with interme-
diate prognosis. However, in a multivariate analysis, only CD44
and disease stage are independent prognostic factors. The develop-
ment of simple and reliable micromethods, such as immunochem-
istry, allows the determination ofdifferent parameters on the same
samples in routine examination. Optimally, these methods will
enable comparison ofthe prognostic values ofthe different biolog-
ical and clinical parameters in a multicentred prospective study
and confirmation ofthe current data.
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